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A B S T R A C T
Hepatitis B virus (HBV) infection is a major global health burden as chronic hepatitis B (CHB) is associated with
the development of liver diseases including hepatocellular carcinoma (HCC). To gain insight into the mechan-
isms causing HBV-related HCC, we investigated the eﬀects of HBV replication on global host cell gene expression
using human HepG2 liver cells. By microarray analysis, we identiﬁed 54 diﬀerentially expressed genes in HBV-
replicating HepG2 cells. One of the diﬀerentially-expressed genes was insulin-like growth factor binding protein
1 (IGFBP1) which was downregulated in HBV-replicating cells. Consistent with the gene expression data, IGFBP1
was suppressed at both the cellular and secreted protein levels in the presence of HBV replication. Transient
transfection experiments with an inducible plasmid encoding the HBV X protein (HBx) revealed that HBx alone
was suﬃcient to modulate IGFBP1 expression. Small interference RNA (siRNA)-mediated loss of function studies
revealed that knockdown of IGFBP1 reduced apoptosis induced by either thapsigargin (TG) or staurosporine
(STS). Treatment of cells with recombinant insulin-like growth factor 1 (IGF-1) decreased both TG- or STS-
induced apoptosis. Interestingly, addition of recombinant IGFBP1 reversed the anti-apoptotic eﬀect of IGF-1 on
TG-induced, but not STS-induced, apoptosis. In conclusion, our results suggest an anti-apoptotic autocrine
function of HBV-mediated downregulation of IGFBP1 in HepG2 cells. Such an eﬀect may contribute to the
development of HBV-mediated HCC by increasing pro-survival and anti-apoptotic IGF-1 eﬀects.
1. Introduction
Hepatitis B virus (HBV) infection continues to be a global burden
with more than 250 million chronic carriers worldwide causing nearly
1 million deaths each year due to complications such as cirrhosis and
hepatocellular carcinoma (HCC) [1]. Especially, the small non-struc-
tural HBV X protein (HBx) is believed to contribute to the development
of HCC by interfering with numerous host proteins including tran-
scription factors [2]. In relation to HBV-related HCC, the eﬀects of HBV
and in particular HBx on apoptosis signaling have been extensively
studied. However, the results have been contradictory and both in-
hibition and induction of apoptosis by HBx have been reported [3–7].
This is presumably due to diﬀerences in experimental conditions and/or
speciﬁc HBV genotypes investigated. More speciﬁcally, HBx has been
found to modulate p53 and NFκB signaling, the PI3K-Akt pathway as
well as both the mitochondrial and the death receptor-mediated
apoptotic pathways (reviewed in [8]). However, the exact molecular
mechanisms responsible for the outcome of a chronic HBV infection are
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T
still unclear. Insight into the possible eﬀects of HBV on host cell gene
expression may identify novel causative mechanisms.
Insulin-like growth factor 1 (IGF-1) is an important growth hor-
mone, which activates pro-survival signaling via binding to the IGF-1
receptor (IGF-1R) [9,10]. The bioavailability of IGF-1 in the blood-
stream is modulated by insulin-like growth factor binding proteins
(IGFBPs) such as IGFBP1 [11,12] and altered IGF-signaling has been
associated with HCC [13]. Hence, IGFBP1 inhibits the growth of human
HCC cell lines [14] and low expression of IGFBP1 in HCC tissue is as-
sociated with a poor prognosis [15]. Hepatitis B virus infection has
previously been found to modulate IGF-signaling e.g. by HBx-mediated
upregulation of IGF-2 and IGF-1R expression [16–18]. Further, changes
in IGFBP1 expression levels have been associated with HBV infection
although results have been conﬂicting [19–24].
In this study, we used human HepG2 liver cells to identify genes
with altered expression in the presence of HBV replication in vitro with
particular focus on genes engaged in pathways associated with cancer
development, such as proliferation and cell death.
We found that HBV replication led to decreased cellular and se-
creted IGFBP1 protein levels. Functional experiments provided evi-
dence for an important autocrine role of IGFBP1 in the regulation of the
pro-survival and anti-apoptotic actions of IGF-1 in HepG2 cells – a
mechanism which may contribute to the development of HCC.
2. Materials and methods
2.1. Cell lines and cell culture
The Human Hepatoma HepG2 tet-on control cell line (HepG2 Tet-
On Advanced cell line, #631150, CloneTech Laboratories, Mountain
View, California, USA) containing the Tet-on inducible gene expression
system [25,26] was stably transfected with the 3091 HBV genome
(genotype D, serotype ayw3) [27]. The doxycycline-responsive pro-
moter controls transcription of the preC/Core (including HBeAg) and
polymerase genes, while HBs and HBx genes are transcribed con-
tinuously. Addition of doxycycline (1 µg/ml) to the media activates
HBV replication and mature virus particles are produced. The un-
transfected HepG2 tet-on cell line was used as control.
Cells were maintained in Dulbecco Modiﬁed Eagle Medium (DMEM)
(#41966–029, Gibco® by Life Technologies, Carlsbad, California, USA)
with 10% Fetal Bovine Serum Premium (#p30–3302, PAN Biotech,
Aidenbach, Germany), 1% Penicillin/Streptomycin (P/S) and G418
(100 µg/ml) at 37 °C with 5% CO2. Puromycin (0.5 µg/ml) was added to
HBs/HBx and HBV cells.
2.1.1. Veriﬁcation of HBV replication
HBV DNA was isolated from the growth medium using the High
Pure Viral Nucleic Acid kit (#11858874001, Roche, Basel, Switzerland)
following the manufacturer's instructions and detected by qPCR (Forw.:
5′-actaggaggctgtaggcata-3′, rev.: 5′-agactctaaggcttcccg-3′). HBsAg and
HBeAg secretion was veriﬁed using speciﬁc immunoassays.
2.1.2. Treatments and stimulations
HepG2 tet-on cells were exposed for 48 h to 0.1 µg/ml recombinant
human IGF-1 (#AFL291-200, R&D Systems, Minneapolis, Minnesota,
USA) and/or 1 µg/ml recombinant human IGFBP1 (#871-B1–025, R&D
Systems). To inhibit the function of IGFs experimentally, IGFBP1 must
either be phosphorylated or present in excess (4:1) [12]. In our ex-
periments we added IGFBP1 to IGF-1 in a ratio of 10:1. Apoptosis was
induced by a 24-h treatment with thapsigargin (#A2229,0001, PanReac
AppliChem, Darmstadt, Germany) or staurosporine (Sigma Aldrich, St.
Louis, Missouri, USA).
2.2. Transfection with siRNA
HepG2 tet-on cells were reverse-transfected with 10 nM ON-
TARGETplus SMARTpool siRNA (mixture of 4 siRNA) (GE Healthcare
Darmacon Inc., Lafayette, Colorado, USA) using Lipofectamine™
RNAiMAX transfection reagent (Invitrogen, Carlsbad, California, USA).
In short, siRNA and Lipofectamine RNAiMAX (0.03 µl/µl OptiMEM)
was dissolved separately in Gibco® Opti-MEM® I Reduced Serum Media
(Life Technologies) and incubated for 5min at RT before mixing in a 1:1
ratio. After 20min of incubation at RT, the siRNA – Lipofectamine
RNAiMAX solution was added to each well. HepG2 tet-on cells in
DMEM with 10% FBS without P/S was then added to each well
(30000–37500 cells/cm2) and the plate gently rocked to mix. After 24 h
of incubation the transfection medium was changed to DMEM with 10%
FBS and 1% P/S.
2.3. Transfection with plasmids
HepG2 tet-on cells were transfected in suspension using the SF Cell
Line 4D-Nucleofector™ X kit (Lonza, Basel, Schweiz) and the Amaxa™
4D-Nucleofector™ X Unit (Lonza) following the manufacturer's in-
structions. In short, 1 million cells were resuspended in 100 µl of
Nucleofector™ SF solution containing 1 µg plasmid and transferred to a
Nucleocuvette to be transfected using the EH-100 program. Post
transfection, 200 µl RPMI growth medium was added and cells left for
10min at 37 °C to recover before plating in pre-warmed DMEM with
10% FBS without P/S. The next day, the medium was changed to
medium with or without doxycycline to induce HBx expression. Cells
were harvested after another 48 h.
2.4. Microarray analysis
Microarray analysis was performed by AROS Applied Biotechnology
A/S using the HumanHT-12 v4.0 Expression BeadChip (Illumina®
Whole-Genome Gene Expression Direct Hybridization Assay system).
This microarray includes 47,000 probes to detect the expression of
34,695 transcripts including known splice variants across the human
transcriptome.
Cells were cultured in DMEM with only 2% serum to reduce the risk
of FCS RNA interference [28]. Lysates were colleted after 48 h and
stored at − 80 °C until RNA isolation using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). RNA concentrations were measured on the
NanoDrop 2000c spectrophotometer (Thermo Fisher Scientiﬁc™, Wal-
tham, Massachusetts, USA). RNA integrity (RIN>1.8) was evaluated
on an Agilent 2100 Bioanalyzer using the RNA 6000 Nano-kit (Agilent
Technologies, Waltham, Massachusetts, USA). Microarray analysis was
performed on three independent replicates.
2.4.1. Statistical analysis
Raw gene-based signal intensities were extracted from
GenomeStudio Gene Expression module. Raw data were corrected for
background noise using the normexp method [29] and quantile nor-
malized [30] using both negative and positive control probes. Genes
that were not expressed were ﬁltered using a criteria of expression in at-
least three samples according to the detection p-value of 5%. Diﬀer-
ential expression analysis was performed using LIMMA [31]. P-values
were adjusted for multiple comparisons using the Benjamini Hochberg
method to control for the false discovery rate (FDR). Diﬀerentially ex-
pressed genes were identiﬁed using the double-ﬁltering criterion: ad-
justed P-value (FDR)< 0.05 and an absolute Log fold change (absolute
Log2(FC))> 1. The statistical analyses were performed with Bio-
conductor in the R statistical environment [32].
2.5. RNA extraction
Total RNA was extracted from cell lines using RNeasy Mini Kit
(Qiagen). Manufacturer's instructions were followed. RNA concentra-
tions were determined and evaluated using the NanoDrop 2000c
spectrophotometer (Thermo Fisher Scientiﬁc™). RNA samples were
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stored at − 80 °C.
2.6. cDNA synthesis and quantitative Real-Time PCR
cDNA synthesis was performed using iSqript™ cDNA Synthesis kit
(BioRad, Hercules, California, USA) in accordance with the manufac-
turer's instructions on a GeneAmp PCR System 9700 (Applied
Biosystems, Foster City, California, USA). Between 250 and 1000 ng
total RNA was used as template in each cDNA synthesis, and blank
samples with H2O as template were included. cDNA was stored at
− 20 °C until further use.
Relative quantiﬁcation of gene expression was performed using
SsoFast™ EvaGreen Supermix (BioRad). Template corresponding to 5 ng
RNA input was used in each reaction and running was performed in
accordance with Manufactorer's instructions on a CFX384 Real-Time
thermal cycler (Biorad). Expression cut-oﬀ was set to Ct< 36. The
geometric mean of GAPDH and ATCB gene expression was used for
normalisation and fold changes were calculated using the 2-ΔΔCt
method. Primers: IGFBP1 (Forw.: 5′-atcctttgggacgccatcag-3′, rev.: 5′-
attccaagggtagacgcacc-3′), HBx (Forw.: 5′-cttctcggggtcgcttgg-3′, rew.: 5′-
cacacggtccggcagatga-3′), GAPDH exon 10–10 (Hs. PT.58.589810.g,
Integrated DNA Technologies, Coralville, Iowa, USA), ACTB exon 6–6
(Hs. PT.56a.40703009.g, Integrated DNA Technologies).
2.7. Western blotting
Cells were lysed directly in wells using M-PER® Mammalian Protein
Extraction Reagent (#78501, Thermo Fisher Scientiﬁc™) with Halt™
Protease & Phosphatase inhibitor Cocktail (Thermo Fisher Scientiﬁc™)
following manufacturer's instructions. Lysates were centrifuged at
14,000×g for 10min and the supernatants (whole cell lysates) col-
lected and stored at − 80 °C. Protein concentrations were determined
using the DC™ Protein Assay (BioRad) according to the manufacturer's
instructions. Loading: 20 µg protein per lane. Secondary HRP-con-
jugated antibodies were used and immune complexes were detected by
chemiluminescence. Images were captured digitally using a FUJI
LAS4000 imaging system (Fujiﬁlm) and band intensities quantiﬁed
using ImageQuant TL. GAPDH was used for normalisation.
Primary antibodies: IGFBP1 (EPR14472(B)) (ab181141, Abcam,
Cambridge, United Kingdom), p-AKT1/2/3 (Ser 473)-R (#sc-7985-R,
Santa Cruz Biotechnology), GAPDH (6C5) (#ab8245, Abcam).
Secondary antibodies: Anti-rabbit IgG, HRP-linked Antibody
(#7074 S, Cell Signaling Technology, Danvers, Massachusetts, USA)
and Anti-mouse IgG, HRP-linked Antibody (#7076 S, Cell signaling
Technology). Protein size was veriﬁed using MagicMark™ Prestained
Protein Ladder (#10748–010, Invitrogen).
2.8. IGFBP1 ELISA
IGFBP1 levels were measured in the culture medium collected after
48 h using a Human IGFBP-1 ELISA Kit (#EHIGFBP1, Thermo Fisher
Scientiﬁc™) according to the instructions of the manufacturer. Prior to
performing the assay, virus was inactivated by adding Triton-X to a
10% ﬁnal concentration and samples had been stored at − 80 °C.
2.9. Cell death measurements
Caspase 3/7 activity was measured in duplicates in 96 well plates
using the Caspase-Glo® 3/7 Assay (#G8093, Promega, Madison,
Wisconsin, USA). In short, Caspase-Glo solution was added to the media
in a 1:1 ratio, shaken for 30 s and incubated for 15min at RT.
Luminescence was measured on a TECAN inﬁnite M200PRO.
Measurement of total cellular protease activity using the CytoTox-Flour
assay (Promega) was performed after the caspase assay to normalize for
diﬀerences in cell numbers. In short, CytoTox-Flour solution was added
in a 1:3 ratio, shaken for 30 s and incubated 40min in darkness at 37 °C.
Fluorescence was measured on a TECAN, inﬁnite M200PRO.
Background values measured in cell culture medium with Caspase-Glo
solution was subtracted all values.
Cell Death detection ELISAPLUS (#11920685001, Roche), de-
termining the cytoplasmic fraction of mono- and oligonucleosomes in
cell lysates, was performed according to the instructions of the manu-
facturer. In short, cells were lysed directly in wells and lysates from
duplicates collected and pooled. Each sample was measured in dupli-
cates on a TECAN inﬁnite M200PRO. The ELISA results were normal-
ized to the DNA levels in the lysates measured after ultrasound soni-
cation using the QuantiFlour dsDNA System kit (E2670, Promega,
Madison, Wisconsin, USA) following the manufacturer's instructions.
2.10. Statistics
Unless stated otherwise, the statistical analyses were performed in
Prism version 7.02 (Graphpad Software Inc, La Jolla, California, USA).
One-way ANOVA (no pairing) was used to analyze data from the three
cell lines, while one-way ANOVA with repeated measures (RM) was
used to analyze data from siRNA transfection and IGF-1/IGFBP1 in-
cubation experiments in the HepG2 tet-on cell line. All ANOVA analyses
were corrected for multiple comparisons using the Bonferroni method.
In case of comparison of only two conditions two-tailed paired Student's
t-test was applied. All data is presented as means± SEM. P-values
≤ 0.05 were considered statistically signiﬁcant (p≤ 0.05 *,
p≤ 0.01 ** and p≤ 0.001 ***).
3. Results
3.1. HBV replication in vitro alters host cell gene expression
To investigate the eﬀect of HBV on host cell gene expression, we
used human liver HepG2 cells with doxycycline-inducible HBV re-
plication. Addition of doxycycline to the culture medium leads to the
production of mature virus particles (designated “HBV cells” in the
following), while viral surface proteins (HBs) and HBx are transcribed
continuously in the absence of doxycycline (designated “HBs/HBx
cells”). Induction of HBV replication upon doxycycline treatment of the
cells was veriﬁed by measuring the levels of HBsAg, HBeAg and HBV
DNA in the growth medium (Table 1).
Microarray gene expression analysis was performed on total RNA to
measure diﬀerences in gene expression in HBs/HBx and HBV cells
compared to HepG2 tet-on control cells. After normalisation and
background correction 16,146 genes were found to be expressed in the
Table 1
Veriﬁcation of HBV-replicating cells. Growth medium was harvested after 48 h and HBV DNA detected by qPCR. Fold changes (FC) were calculated using the 2-ΔCt
method. Data are means± SEM of 4 independent experiments. HBsAg and HBeAg secretion to the media were detected as signal to cut-oﬀ (S/CO) by speciﬁc
immunoassays.
HBV DNA (FC) (Mean± SEM) HBsAg (S/CO) (Cut-oﬀ: 0.13) HBeAg (S/CO) (Cut-oﬀ: 0.1)
HepG2 tet-on cells 1.00 ± 0.00 0.01 0.00
HBs/HBx cells 1.00 ± 0.00 1.83 0.01
HBV cells 92.31 ± 21.56 1.62 1.14
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cell lines using a detection p-value cut-oﬀ< 0.05. We found 54 genes
signiﬁcantly upregulated (≥ 2-fold) or downregulated (≤ 0.5-fold) in
the presence of full HBV replication compared to the control after
correction for multiple comparisons (FDR<0.05) (Fig. 1 and Table 2).
Interestingly, 32 of these genes were also diﬀerentially expressed in
HBs/HBx cells. In total, 42 genes were signiﬁcantly diﬀerentially ex-
pressed in HBs/HBx cells compared to the HepG2 tet-on control
(Table 2). No genes were found diﬀerentially expressed between the
HBs/HBx and HBV cells after correction for multiple comparisons (FDR
≤ 0.05). These results suggest that the presence of HBs and HBx, and
not full virus replication, is suﬃcient to cause the majority of the host
cell gene expression changes.
3.2. HBV decreases the cellular and secreted levels of IGFBP1
Among the identiﬁed genes found to be diﬀerentially expressed in
HBV cells were insulin-like growth factor binding protein 1 and 7
(IGFBP1 and IGFBP7). These genes seem particularly interesting with
regard to the development of HBV-related liver cancer, as IGFBPs are
known to bind to and modulate the action of Insulin-like growth factors
(IGFs), which are important regulators of cell survival, growth, and
apoptosis through the PI3K/AKT signaling pathway [9]. According to
The Human Protein Atlas [33,34], IGFBP1 is mainly expressed in the
liver, while IGFBP7 is expressed in many diﬀerent tissues. This
prompted us to examine the role and function of IGFBP1 in HepG2 cells
in the presence or absence of HBx/HBs or HBV replication.
In line with the microarray results, RT-qPCR and western blotting
conﬁrmed downregulation of IGFBP1 in both HBs/HBx and HBV cells as
compared to HepG2 tet-on control cells (Fig. 2A and B). Accordingly, a
signiﬁcantly reduced secretion of IGFBP1 to the culture medium was
observed in both HBV cells and HBs/HBx cells as compared to control
cells (Fig. 2C).
The eﬀect of HBV and particularly HBx on IGFBP1 expression has
previously been studied in diﬀerent HBV and HBx model systems,
however, the results have been contradictory [19–24]. One factor that
could account for the reported discrepancies between diﬀerent models
is diﬀerences in the expression level of HBx. We therefore in more detail
investigated the relationship between the level of HBx and IGFBP1
expression. HepG2 tet-on cells were transiently transfected with either a
doxycycline-inducible HBx-expression plasmid or an empty plasmid as
control. High transfection eﬃciency was veriﬁed by GFP expression
48 h after transfection with a GFP plasmid (Suppl. Fig. 1). A con-
centration-dependent doxycycline-inducible HBx expression was con-
ﬁrmed by RT-qPCR (Fig. 2D). Due to leakiness of the tet-on system [35],
a low level of HBx was also detected without doxycycline induction.
Interestingly, we found that both the mRNA and protein levels of
IGFBP1 decreased in response to induction of HBx expression by dox-
ycycline (Fig. 2E and F). At a low HBx level the expression level of
IGFBP1 was increased compared to the empty vector control cells,
while the level of IGFBP1 decreased at higher levels of HBx. These data
indicate that the impact of HBx on the expression of IGFBP1 depends on
the exact expression level of HBx.
3.3. Knockdown of IGFBP1 reduces apoptosis in HepG2 cells
IGF-1 protects HepG2 cells from apoptosis induced by doxorubicin
[13], but to our knowledge the potential apoptosis-regulatory role of
IGFBP1 has not previously been investigated in HepG2 cells. To in-
vestigate the eﬀect of decreased IGFBP1 expression on apoptosis, we
transfected HepG2 tet-on cells with an IGFBP1-speciﬁc siRNA pool
(siIGFBP1) or non-targeting siRNA (siCTRL) as a negative control. The
IGFBP1 knockdown eﬃciency by the siRNA pool was veriﬁed at both
the mRNA and protein levels after 48 h (Fig. 3A and B). To induce
apoptosis, we used thapsigargin (TG) and staurosporine (STS), two
well-known apoptosis inducers. TG is an inhibitor of the sarcoendo-
plasmic reticulum calcium transport ATPase (SERCA) pump, leading to
endoplasmic reticulum (ER) stress and subsequent apoptosis [36]. STS
is a protein kinase C inhibitor causing mitochondrial dysfunction
leading to apoptosis [37]. Treatment of HepG2 cells with TG or STS
lead to an upregulation of IGFBP1 expression (Fig. 3B and Suppl.
Fig. 2), which is consistent with what other studies have reported
[38–41]. Interestingly, we found that both STS- and TG-induced cas-
pase-3/7 activity were signiﬁcantly lower in cells with knockdown of
IGFBP1 (Fig. 3C). Although statistically signiﬁcant, the apoptosis-low-
ering eﬀects of IGFBP1 knockdown were modest. However, focusing on
the induced apoptosis and calculating the percentage of inhibition after
subtraction of basal levels of caspase activity, knockdown of IGFBP1
inhibited caspase activity up to 35% (Fig. 3D). These data were con-
ﬁrmed measuring cell death as determined by the level of cytoplasmic
nucleosomes (Fig. 3E and F). These results indicate that IGFBP1 has a
pro-apoptotic function, possibly by inhibiting the pro-survival eﬀects of
IGF-1.
3.4. IGFBP1 inhibits IGF-1-mediated protection against TG-induced
apoptosis
IGFBP1 is known to have both IGF-dependent and -independent
functions [11]. To investigate whether the protective eﬀect following
knockdown of IGFBP1 is IGF-dependent, HepG2 tet-on cells were pre-
stimulated with recombinant human IGF-1 and/or IGFBP1 for 24 h
before inducing apoptosis. Since serum contains IGFs, these experi-
ments were performed under serum-free or low serum (2% FBS) con-
ditions. Furthermore, because IGF-1 is known to stimulate cell growth,
caspase activity was normalized to cell numbers by measuring cellular
protease activity using a cytotox assay found to have a linear correla-
tion to the cell count (Suppl. Fig. 3A). As expected, cell growth was
aﬀected by both IGF-1 and/or IGFBP1 especially under serum-free
conditions (Suppl. Fig. 3B and C). We found that TG-induced caspase-3/
7 activity was slightly, but signiﬁcantly reduced by IGF-1 – an eﬀect
that was only present under serum-free conditions (Fig. 4A and B). The
protective eﬀect of IGF-1 was more prominent when using a lower TG
concentration (Fig. 4C). The combination of IGF-1 and IGFBP1 negated
the protective eﬀect of IGF-1 alone (Fig. 4A and C). These data suggest
that the protective eﬀect of knockdown of IGFBP1 on TG-induced
apoptosis is mediated via increased IGF-1 anti-apoptotic eﬀects.
To conﬁrm active IGF-1 signaling upon treatment with IGF-1, we
Fig. 1. Gene expression in HBV-replicating cells.
Volcano plot of diﬀerential gene expression in HBV cells compared to HepG2
tet-on control cells. Cut-oﬀ was set at FDR ≤ 0.05 and an absolute log2 fold
change (FC)> 1. Data are means of 3 independent experiments.
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Table 2
Gene expression in HBV-replicating and HBs/HBx cells. Diﬀerentially expressed genes in HBV cells and HBs/HBx cells compared
to HepG2 tet-on cells after correction for multiple comparisons. Cut-oﬀ was set at FDR ≤ 0.05 and an absolute log2 fold change
(FC)> 1 (black font). For genes only signiﬁcantly diﬀerentially expressed in either HBV cells or HBs/HBx cells, the corresponding
data is in grey font. Mean of 3 independent experiments.
(continued on next page)
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examined the protein level of phosphorylated AKT (p-AKT) by western
blotting after IGF-1 treatment with and without TG exposure (Fig. 4D).
A signiﬁcantly increased level of p-AKT was detected both under serum-
free and low serum conditions (Fig. 4D) conﬁrming the stimulatory
eﬀect of IGF-1 treatment on HepG2 tet-on cells. Notably, TG exposure
caused a marked decrease in the level of p-AKT (Fig. 4D).
Interestingly, as opposed to that observed for TG-induced apoptosis,
IGFBP1 did not negate the protective eﬀect of IGF-1 on STS-induced
caspase activity (Fig. 4E), suggesting that the protective eﬀect of
knockdown of IGFBP1 on STS-induced apoptosis is IGF-1-independent.
4. Discussion
Chronic hepatitis B infection is associated with a high risk of de-
veloping severe liver disease including cirrhosis and HCC. However,
little is known about the molecular mechanisms involved in the de-
velopment of these diseases. In this study, we investigated the impact of
HBV replication on global host cell gene expression by microarray
analysis and identiﬁed 54 diﬀerentially expressed genes in HBV-re-
plicating HepG2 cells. These ﬁndings support the concept that HBV
contributes to altered host cell gene expression that may contribute to
the pathogenesis of liver disease such as HCC.
Two of the diﬀerentially expressed genes were IGFBPs, including
IGFBP1, known to be regulators of IGF activity. We chose to focus on
IGFBP1 for several reasons; i) it is speciﬁcally expressed in the liver
[33,34], ii) altered IGF signaling is associated with HCC [13], iii)
IGFBP1 inhibits the growth of human HCC cell lines [14], and iv) low
expression of IGFBP1 in HCC tissue is associated with a poor prognosis
[15]. We conﬁrmed that IGFBP1 is downregulated at both the cellular
and secreted protein levels in HBs/HBx and HBV cells compared to
control cells. Speciﬁcally, the eﬀect of HBx on IGFBP1 expression was
found to depend on the HBx expression level. Knockdown of IGFBP1 in
HepG2 tet-on cells reduced both TG- and STS-induced apoptosis as re-
vealed by decreased caspase 3/7 activity and lower levels of cyto-
plasmic levels of nucleosomes, both of which are characteristics of
apoptosis. Furthermore, addition of recombinant IGFBP1 to the culture
medium reversed the protective eﬀect of IGF-1 on TG-induced apop-
tosis, but not STS-induced apoptosis. Altogether, this suggests a pro-
apoptotic eﬀect of IGFBP1 in HepG2 tet-on cells partly through the
inhibition of IGF-1 signaling.
The decreased level of IGFBP1 found in the HBs/HBx cells indicates
Table 2 (continued)
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that the presence of HBs and HBx proteins is suﬃcient to suppress
IGFBP1 expression. Both HBs and HBx have previously been shown to
modulate the host environment [42,43]. The eﬀect of HBV infection on
IGFBP1 expression has been investigated previously, but the results
have been contradictory. In primary human hepatocytes (PHH) infected
with HBV, the expression of IGFBP1 has been found upregulated,
however, this could not be conﬁrmed in tissue from HBV patients [19].
In HBx-transgenic mice, IGFBP1 has been found both up- and down-
regulated [21,22]. In hepatocytes from humanized chimeric mice
transfected with HBV, IGFBP1 expression was increased [20]. In plasma
from HBV-infected children with cirrhosis, IGFBP1 was upregulated
[23], while IGFBP1 was downregulated in HBV-related HCC tissue [24].
Interestingly, we found that in the inducible HBx-expressing cells the
IGFBP1 expression level inversely correlated with the HBx expression
level. However, compared to Mock cells, the HBx-expressing cells had
higher IGFBP1 expression even in the absence of doxycycline. This
suggests a bell-shaped association between HBx and IGFBP1 expression.
This ﬁnding may explain the discrepancy between results in the lit-
erature as diﬀerent HBV models might have diﬀerent HBx expression
levels. Furthermore, it could be speculated that changes in HBx ex-
pression levels during the pathogenesis of chronic hepatitis B could
aﬀect IGFBP1 expression.
Fig. 2. IGFBP1 expression and secretion in HBV-replicating and HBs/HBx cells Growth media and cell lysates were collected after 48 h. A: IGFBP1 mRNA level was
measured by RT-qPCR. Data are means± SEM of 7 independent experiments. Statistics: One-way ANOVA, corrected for multiple comparisons (Bonferroni). B:
IGFBP1 protein level was measured by western blotting and quantiﬁed (normalized to GAPDH). Data are means± SEM of 4 independent experiments. Statistics:
One-way ANOVA, corrected for multiple comparisons (Bonferroni). C: IGFBP1 protein secretion to the culture medium detected with ELISA. Data are means± SEM
of 4 independent experiments. Statistics: One-way ANOVA, corrected for multiple comparisons (Bonferroni). HepG2 tet-on cells were transiently transfected with a
doxycycline-inducible HBx-expression plasmid (grey bars) or an empty plasmid (mock) (black bars). D: HBx mRNA expression was measured by RT-qPCR. Data are
means± SEM of 6 independent experiments. Statistics: RM One-way ANOVA, corrected for multiple comparisons (Bonferroni). IGFBP1 mRNA (E) and protein (F)
levels were measured by RT-qPCR and western blotting, respectively. Data are means± SEM of 6 independent experiments. Statistics: Two-way ANOVA, corrected
for multiple comparisons (Bonferroni).
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It has been reported that the Tet-on system, even in the absence of
doxycycline, causes low transcription from the tetracycline-inducible
promoter [35]. In the case of the HBs/HBx cells this would give a low
level of HBV replication. This fact could explain why no signiﬁcant
changes in gene expression were found between HBs/HBx and HBV
cells. Thus, we cannot exclude the possibility that the observed changes
in gene expression in the HBs/HBx cells are caused by a low level of
HBV replication and not solely by the HBs and HBx proteins. However,
the negative inverse expression correlation found between IGFBP1 and
HBx nevertheless indicates that HBx alone is suﬃcient to modulate
IGFBP1 expression in HepG2 cells.
We found that IGF-1 signiﬁcantly reduced TG- and STS-induced
apoptosis under serum free conditions, although the eﬀect was only
modest after treatment with TG. An explanation for this could be that
the level of IGFBP1 was strongly increased in response to TG and STS
treatment, potentially leading to a higher level of IGFBP1 in the media
counteracting the eﬀect of IGF-1 stimulation. Consistent with our re-
sults, IGFBP1 expression has previously been shown to dynamically
change in response to ER stress [41] and pro-inﬂammatory cytokines
[39]. In HepG2 cells upregulation of IGFBP1 expression may therefore
be a general cellular response to inducers of stress and apoptosis. The
fact that co-incubation with IGFBP1 and IGF-1 negated the protective
eﬀect of IGF-1 alone on TG-induced apoptosis suggests that in HepG2
tet-on cells, IGFBP1 can inhibit the anti-apoptotic eﬀects of IGF-1.
However, as co-incubation with IGFBP1 and IGF-1 failed to reverse the
protective eﬀect of IGF-1 alone on STS-induced apoptosis, IGFBP1
likely also has IGF-1-independent functions in HepG2 cells.
Although the observed reductions in TG- and STS-induced apoptosis
mediated by knockdown of IGFBP1 or addition of IGF-1 may not appear
pronounced, it is important to keep in mind that the development of
Fig. 3. Knockdown of IGFBP1 reduces apoptosis
HepG2 tet-on cells were transfected with siIGFBP1 or
siCTRL. Lysates were collected and apoptosis mea-
sured after 48 h. A: Veriﬁcation of siRNA knockdown
on mRNA level by RT-qPCR. Data are means± SEM of
6 independent replicates. Statistics: two-tailed paired
Student's t-test. B: Veriﬁcation of siIGFBP1 knockdown
by western blotting. Representative blot of 4 in-
dependent experiments are shown. C: Caspase-3/7
activity after 24 h of treatment with diﬀerent con-
centrations of thapsigargin (TG) or staurosporine
(STS). Data are means± SEM of 7–8 independent
experiments. D: Percent caspase-3/7 activity to con-
trols after subtraction of basal caspase activity level. E:
Cell death after 24 h treatment with diﬀerent con-
centrations of TG or STS. Data are means± SEM of
7–8 independent experiments. F: Percent cell death to
controls after subtraction of basal cell death level.
Statistics: two-tailed paired Student's t-test to individual
controls.
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HBV-related liver diseases like HCC is a slow process going on for years.
Therefore, even small changes in activity of the IGF1-signaling pathway
may well contribute to the malignancies caused by CHB.
In conclusion, using a HepG2 HBV model system, our ﬁndings
suggest that HBV via HBx suppresses host cell expression and secretion
of IGFBP1 thereby allowing increased IGF-1-dependent and -in-
dependent pro-survival and anti-apoptotic eﬀects that may contribute
to HBV-associated liver malignancies including HCC.
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